期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 62, 期 25, 页码 D22-D33出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.10.027
关键词
echocardiography; heart failure; MRI; myocardium; pulmonary artery hypertension; right ventricle
资金
- Actelion
- Bayer
- GlaxoSmithKline
- United Therapeutics
- Lilly
- Pfizer
- Novartis
- Gilead
- GeNO
- National Institutes of Health
- Dutch Heart Foundation [NHS-2012T010]
- AIRES
- Ikaria
- Lung LLC
- Unither Biotech
- AOP
- National Heart, Lung, and Blood Institute [P50 HL084946, R01 HL114910]
Survival in patients with pulmonary arterial hypertension (PAH) is closely related to right ventricular (RV) function. Although pulmonary load is an important determinant of RV systolic function in PAH, there remains a significant variability in RV adaptation to pulmonary hypertension. In this report, the authors discuss the emerging concepts of right heart pathobiology in PAH. More specifically, the discussion focuses on the following questions. 1) How is right heart failure syndrome best defined? 2) What are the underlying molecular mechanisms of the failing right ventricle in PAH? 3) How are RV contractility and function and their prognostic implications best assessed? 4) What is the role of targeted RV therapy? Throughout the report, the authors highlight differences between right and left heart failure and outline key areas of future investigation. (C) 2013 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据